子宫内生长对早产婴儿凝血和XII因子功能的影响
Şükran Yildirim1, Asuman Çoban2, Ayşegül Ünüvar3
1Istanbul Prof. Dr Cemil Tascioglu City Hospital, Neonatal Intensive Care Unit, University of Health Sciences.
概括
宫内生长限制 (IUGR) 显著改变了早产婴儿的凝血,特别是那些出生在32周之前的婴儿. 较低的关键凝血因子和较高的XII因子水平表明新鲜冷血可能对出血风险有益.
科学领域:
- 新生儿医学 新生儿医学
- 血液学 血液学 血液学
- 周围生理学 周围生理学
背景情况:
- 胎内生长限制 (IUGR) 是早产新生儿的一个重大问题.
- 凝血障碍在早产婴儿中很常见,可能会被IUGR加剧.
- 了解这些影响对于管理出血风险和治疗策略至关重要.
研究的目的:
- 研究IUGR对早产新生儿凝血概况的特定影响.
- 评估新鲜冷血在这些婴儿的管理中的潜在作用.
- 为了将凝血变化与妊娠年龄和心室内出血的发生率相关联.
主要方法:
- 对30名早产婴儿的凝血因子的比较分析,IUGR与32名没有.
- 在出生后4小时内进行血液样本分析,包括凝血因子,血液气体和CBC.
- 使用SPSS版本15对群体之间的差异的统计评估.
主要成果:
- 患有IUGR的早产婴儿,尤其是32周前出生的婴儿,表现出明显较低的凝血因子V,VII,XIII和抗血III水平.
- 在IUGR婴儿中观察到高水平的VIII因子和延长的血栓形成时间.
- 在所有早产婴儿中,IUGR的XII因子水平显著更高,可能与缺氧和炎症有关.
结论:
- IUGR对新生儿凝血有深远的影响,特定的凝血因子有明显的改变.
- 传统的凝血试验可能无法完全预测IUGR早产婴儿的出血,但有助于评估心室内出血风险.
- 给出新鲜冷血对于患有IUGR的出血早产婴儿,特别是32周前出生婴儿,是一个可行的考虑因素.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
536
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
536
01:20Extrinsic and Intrinsic Pathways of Hemostasis
3.6K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
3.6K
01:09Coagulation
3.2K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
3.2K
01:16Clot Retraction and Fibrinolysis
2.4K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
2.4K
01:24Disorders of Hemostasis
638
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
638